20/20 Biolabs annual shares outstanding
2023
2024
2025
20/20 Biolabs Shares Outstanding History (AIDX)
20/20 Biolabs reported 5.4M shares outstanding at the end of fiscal 2025.
View full 20/20 Biolabs company overview20/20 Biolabs annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 5.4M | 619,124 | +12.84% |
| 2024 | 2024-12-31 | 4.8M | −5.5M | −53.39% |
| 2023 | 2023-12-31 | 10.3M | — | — |
20/20 Biolabs quarterly shares outstanding
Q4.24
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 12.3M | — | — |
| Q1 2026 | 2026-03-31 | 10.4M | — | — |
| Q4 2025 | 2025-12-31 | 5.4M | 619,124 | +12.84% |
| Q3 2025 | 2025-09-30 | 10.3M | — | — |
| Q4 2024 | 2024-12-31 | 4.8M | — | — |
20/20 Biolabs shares outstanding trends
Between the periods ended 2023-12-31 and 2025-12-31, 20/20 Biolabs's shares outstanding moved from 10.3M to 5.4M, a change of −4.9M. The latest reported quarter, Q2 2026, shows 12.3M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review 20/20 Biolabs source filings ↗